Actively Recruiting
Artificial Tears to Prevent Nasolacrimal Duct Obstruction in Patients Treated With Radioactive Iodine for Thyroid Cancer
Led by Vanderbilt University Medical Center · Updated on 2025-10-28
100
Participants Needed
1
Research Sites
227 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The association of radioiodine therapy for the treatment of thyroid cancer with nasolacrimal duct obstruction has been well documented in the medical literature. Prior case reports have documented radioactive iodine detection in the tears of patients following radioiodine therapy. It is possible that radioactive uptake by the cells in the lacrimal sac and nasolacrimal duct lead to inflammation, fibrosis, and obstruction of the tear duct over time. A recent study has shown that the administration of artificial tears decreases the level of detectable radioiodine in the tears of patients undergoing radioiodine therapy for thyroid cancer. The purpose of this study will be to assess whether administering tears after radioactive iodine therapy for thyroid cancer decreases the incidence of nasolacrimal duct obstruction in the two years following radioactive iodine treatment.
CONDITIONS
Official Title
Artificial Tears to Prevent Nasolacrimal Duct Obstruction in Patients Treated With Radioactive Iodine for Thyroid Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Received radioactive iodine therapy for thyroid cancer
- Radioactive iodine therapy dose of 150 mCi or higher
- Age 18 years or older
You will not qualify if you...
- Use of eye drops other than artificial tears
- History of periocular trauma involving tear ducts or lacrimal gland
- History of lacrimal drainage diseases such as canaliculitis or dacryocystitis
- Prior radiotherapy treatment
- Current or past chemotherapy drug use (e.g., 5-fluorouracil, docetaxel)
- Medical conditions increasing risk of nasolacrimal duct stenosis (e.g., sarcoidosis, granulomatosis with polyangiitis, chronic lymphocytic leukemia)
- Presence of nasolacrimal duct obstruction at the start of the study
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Vanderbilt University Medical Center
Nashville, Tennessee, United States, 37232
Actively Recruiting
Research Team
M
Marybeth Carter
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here